On the basis of the preclinical observation that PTEN loss may increase tumor sensitivity to mTOR inhibition [14,54], the predictive potential of PTEN in BC patients has been explored in the context of several clinical trials testing the mTOR inhibitor Everolimus for metastatic BC, with conflicting results. The gene discussed is MTOR; the disease is neoplasm.